Pharmerica Revenue
Pharmerica revenue was $2.09 b in FY, 2016 which is a 3.1% year over year increase from the previous period.
Summary - Funding Rounds
Founding Date | 2007 |
Investors | KKR & Co. (Kohlberg Kravis Roberts & Co.) |
Pharmerica is a subsidiary of KKR & Co. (Kohlberg Kravis Roberts & Co.)
Pharmerica Income Statement
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 1.8b | 1.9b | 2.0b | 2.1b |
Revenue growth, % | 8% | 7% | 3% | |
Cost of goods sold | 1.4b | 1.6b | 1.7b | 1.8b |
Gross profit | 327.2m | 339.3m | 335.1m | 326.0m |
Gross profit Margin, % | 19% | 18% | 17% | 16% |
General and administrative expense | 220.6m | |||
Operating expense total | 220.6m | |||
EBIT | 55.8m | 30.4m | 53.8m | 38.4m |
EBIT margin, % | 3% | 2% | 3% | 2% |
Interest expense | 10.6m | 9.9m | 6.6m | 9.5m |
Interest income | 10.6m | 9.9m | 6.6m | 9.5m |
Pre tax profit | 45.2m | 16.2m | 47.2m | 28.9m |
Income tax expense | 26.3m | 9.4m | 12.1m | 7.3m |
Net Income | 18.9m | 6.8m | 35.1m | 21.6m |
- Source: Pitchbook
Pharmerica Balance Sheet
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 24.2m | 33.3m | 5.4m | |
Accounts Receivable | 199.8m | 195.7m | 235.4m | |
Inventories | 110.3m | 135.7m | 214.7m | |
Current Assets | 411.7m | 497.3m | 552.4m | |
Goodwill | 282.6m | 317.7m | 371.0m | 392.3m |
Total Assets | 901.4m | 1.1b | 1.3b | |
Accounts Payable | 83.8m | 95.5m | 107.1m | |
Short-term debt | 12.5m | 6.4m | 15.6m | |
Current Liabilities | 151.5m | 175.8m | 182.3m | |
Long-term debt | 218.8m | 344.9m | 457.8m | |
Total Debt | 231.3m | 351.3m | 427.3m | 473.4m |
Additional Paid-in Capital | 380.2m | 394.1m | 411.1m | |
Retained Earnings | 110.2m | 117.0m | 173.7m | |
Total Equity | 462.5m | 478.1m | 544.2m | |
Debt to Equity Ratio | 0.5 x | 0.7 x | 0.9 x | |
Debt to Assets Ratio | 0.3 x | 0.3 x | 0.4 x | |
Financial Leverage | 1.9 x | 2.2 x | 2.4 x |
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 52.4m | 11.1m | 7.1m | 25.2m | 21.3m | 40.0m | 27.4m | 13.5m | 7.8m | ||||
Accounts Receivable | 190.5m | 188.1m | 213.7m | 199.5m | 199.1m | 208.1m | 246.6m | 249.2m | |||||
Inventories | 70.3m | 141.4m | 133.4m | 122.6m | 135.2m | 160.9m | 139.6m | 139.2m | |||||
Current Assets | 390.5m | 435.9m | 466.1m | 449.7m | 450.2m | 494.2m | 430.0m | 457.4m | 455.3m | ||||
Goodwill | 271.4m | 286.9m | 321.5m | 336.3m | 336.8m | 372.2m | 422.9m | 449.3m | |||||
Total Assets | 845.1m | 923.4m | 1.0b | 1.0b | 1.1b | 1.1b | 1.2b | 1.2b | 1.3b | ||||
Accounts Payable | 53.1m | 59.1m | 75.5m | 81.6m | 80.1m | 97.4m | 73.0m | 104.5m | 97.1m | ||||
Short-term debt | 12.5m | 12.5m | 2.8m | 8.9m | 11.6m | 11.6m | 15.5m | 15.4m | |||||
Current Liabilities | 108.5m | 113.0m | 125.6m | 132.4m | 154.8m | 155.2m | 168.4m | 177.8m | 176.3m | ||||
Long-term debt | 221.9m | 256.4m | 358.1m | 317.1m | 338.2m | 326.0m | 366.0m | 400.2m | 451.0m | 417.4m | 444.8m | ||
Total Debt | 234.4m | 230.9m | 268.9m | 360.9m | 326.0m | 349.8m | 337.4m | 377.6m | 411.8m | 390.5m | 466.5m | 432.9m | 460.2m |
Additional Paid-in Capital | 368.9m | 389.7m | 391.9m | 397.9m | 400.1m | 408.5m | 416.0m | 417.7m | 419.3m | ||||
Retained Earnings | 105.8m | 115.0m | 105.3m | 113.8m | 126.6m | 128.9m | 158.7m | 166.0m | 181.9m | 185.1m | |||
Total Equity | 456.7m | 470.0m | 462.2m | 472.7m | 487.1m | 492.1m | 526.9m | 556.8m | 561.6m | ||||
Debt to Equity Ratio | 0.5 x | ||||||||||||
Debt to Assets Ratio | 0.3 x | ||||||||||||
Financial Leverage | 1.9 x | 2 x | 2.2 x | 2.1 x | 2.1 x | 2.3 x | 2.2 x | 2.3 x |
Pharmerica Cash Flow
Annual
| USD | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|
Net Income | 6.8m | 21.6m | |
Depreciation and Amortization | 20.3m | 33.7m | |
Accounts Receivable | 29.1m | (34.3m) | |
Inventories | (19.0m) | (56.7m) | |
Accounts Payable | (2.9m) | (24.0m) | 36.4m |
Cash From Operating Activities | 48.4m | 30.8m | |
Cash From Investing Activities | (157.0m) | (91.7m) | |
Long-term Borrowings | (231.3m) | (11.3m) | |
Cash From Financing Activities | 117.7m | 43.2m | |
Interest Paid | 7.8m | 10.6m | |
Income Taxes Paid | 5.3m | (4.8m) |
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q3, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 4.8m | 8.5m | 9.6m | 3.0m | 7.3m | 3.5m | ||||||
Depreciation and Amortization | 4.8m | 4.9m | 5.8m | 5.7m | 11.0m | 6.2m | 6.9m | |||||
Accounts Receivable | 13.1m | (1.0m) | (1.7m) | (2.3m) | 195.8m | 1.0m | (7.0m) | 215.4m | 247.8m | |||
Inventories | 2.8m | (34.0m) | 14.9m | 13.2m | 117.5m | 118.8m | 143.5m | 81.0m | ||||
Accounts Payable | (21.8m) | (2.4m) | (14.1m) | 83.3m | 73.0m | 86.9m | ||||||
Cash From Operating Activities | 4.4m | 19.7m | 44.3m | |||||||||
Cash From Investing Activities | (11.0m) | (16.3m) | (113.4m) | (25.0m) | ||||||||
Long-term Borrowings | (3.1m) | (225.0m) | ||||||||||
Cash From Financing Activities | (27.0m) | 400.0k | 89.7m | (27.4m) | ||||||||
Interest Paid | 2.0m | 1.8m | 1.9m | 2.1m | 3.0m | |||||||
Income Taxes Paid | 400.0k | 1.0m | 4.7m | 17.0m |
Report incorrect company information
Pharmerica Operating Metrics
| FY, 2016 | |
|---|---|
Infusion Centers | 19 |
Pharmacies | 103 |
- Source: SEC Filings
Report incorrect company information
